Alnylam
Exome Sequencing Study Uncovers Rare Variants in Gene Protecting Against Liver Disease
The findings of the study, which was funded by Regeneron Pharmaceuticals, suggest a new treatment for conditions like nonalcoholic steatohepatitis (NASH).
Centogene, Alnylam Pharmaceuticals Partner on Biomarker Study of Transthyretin Amyloidosis
The study, called TRAMmoniTTR, will longitudinally monitor the clinical status of both symptomatic and asymptomatic participants with variants in the TTR gene.
Alnylam, 23andMe Partner on Free Family Testing Program for Hereditary ATTR Amyloidosis
23andMe customers who have one of three common variants identified in reports can choose six family members to receive health and ancestry test kits.
Invitae, Alnylam to Provide Free Genetic Testing for Primary Hyperoxaluria
Through the Alnylam Act program, patients suspected of having the rare disease or with a family history of the illness will receive testing at no cost.
Regeneron Partners With AbbVie, Alnylam, AstraZeneca, Biogen, Pfizer to Sequence UK Biobank Samples
By the end of 2019, Regeneron plans sequence the exomes of all 500,000 participants in the UK Biobank.
Jan 5, 2018
Alnylam Expands Genetic Testing Program
Feb 13, 2015
Feb 2, 2015
Jan 20, 2015
Jan 9, 2015
Dec 15, 2014
Dec 12, 2014
Dec 10, 2014
Dec 10, 2014
Dec 3, 2014
Nov 18, 2014
Nov 17, 2014
Nov 11, 2014
Nov 6, 2014
Nov 6, 2014
Nov 6, 2014
Oct 30, 2014